These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31550797)

  • 1. [Predictive value of plasma PCSK9 levels in acute myocardial infarction patients without reperfusion therapy for recurrence of cardiovascular events within 1 year].
    Gao Y; Zhang HB; Hou LL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(35):2750-2755. PubMed ID: 31550797
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute-Phase Plasma PCSK9 Levels and Recurrent Cardiovascular Events in a Chinese Acute Myocardial Infarction Cohort.
    Gao Y; Qiu Y; Wu J; Diao W; Zhang H; Wang S; Du Z; Dong J; Zhang M; Jiang L
    Cardiology; 2018; 141(2):88-97. PubMed ID: 30423567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
    El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
    Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarction.
    Zeller M; Lambert G; Farnier M; Maza M; Nativel B; Rochette L; Vergely C; Cottin Y
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):880-885. PubMed ID: 33546945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction.
    Zhang Z; Wei TF; Zhao B; Yin Z; Shi QX; Liu PL; Liu LF; Liu L; Zhao JT; Mao S; Rao MM; Wang SL; Chen YD
    Sci Rep; 2019 Feb; 9(1):3113. PubMed ID: 30816133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
    Ridker PM; Rifai N; Bradwin G; Rose L
    Eur Heart J; 2016 Feb; 37(6):554-60. PubMed ID: 26508163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
    Pastori D; Nocella C; Farcomeni A; Bartimoccia S; Santulli M; Vasaturo F; Carnevale R; Menichelli D; Violi F; Pignatelli P;
    J Am Coll Cardiol; 2017 Sep; 70(12):1455-1462. PubMed ID: 28911508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of PCSK9 levels in patients with acute coronary syndromes.
    Gencer B; Montecucco F; Nanchen D; Carbone F; Klingenberg R; Vuilleumier N; Aghlmandi S; Heg D; Räber L; Auer R; Jüni P; Windecker S; Lüscher TF; Matter CM; Rodondi N; Mach F
    Eur Heart J; 2016 Feb; 37(6):546-53. PubMed ID: 26655339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis.
    Vlachopoulos C; Terentes-Printzios D; Georgiopoulos G; Skoumas I; Koutagiar I; Ioakeimidis N; Stefanadis C; Tousoulis D
    Atherosclerosis; 2016 Sep; 252():50-60. PubMed ID: 27501130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis.
    Liberale L; Carbone F; Bertolotto M; Bonaventura A; Vecchié A; Mach F; Burger F; Pende A; Spinella G; Pane B; Camici GG; Palombo D; Dallegri F; Montecucco F
    Int J Cardiol; 2018 Jul; 263():138-141. PubMed ID: 29754909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction.
    Zebrack JS; Anderson JL; Maycock CA; Horne BD; Bair TL; Muhlestein JB;
    Am J Cardiol; 2002 Jan; 89(2):145-9. PubMed ID: 11792332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
    Navarese EP; Kolodziejczak M; Winter MP; Alimohammadi A; Lang IM; Buffon A; Lip GY; Siller-Matula JM
    Int J Cardiol; 2017 Jan; 227():644-649. PubMed ID: 27810295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction.
    Ahn SG; Lee SH; Yoon JH; Kim WT; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Yoon J; Choe KH
    JACC Cardiovasc Interv; 2012 Mar; 5(3):259-67. PubMed ID: 22440490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proenkephalin and prognosis after acute myocardial infarction.
    Ng LL; Sandhu JK; Narayan H; Quinn PA; Squire IB; Davies JE; Bergmann A; Maisel A; Jones DJ
    J Am Coll Cardiol; 2014 Jan; 63(3):280-9. PubMed ID: 24140658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Men from Different Population Groups and Its Relation to Unfavorable Long-Term Prognosis].
    Ragino YI; Astrakova KS; Shakhtshneider EV; Stakhneva EM; Gafarov VV; Bogatyrev SN; Voevoda MI
    Kardiologiia; 2017 Apr; 57(4):72-76. PubMed ID: 28762908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study.
    Xie W; Liu J; Wang W; Wang M; Qi Y; Zhao F; Sun J; Liu J; Li Y; Zhao D
    Int J Cardiol; 2016 Jul; 215():293-8. PubMed ID: 27128549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.
    Leander K; Mälarstig A; Van't Hooft FM; Hyde C; Hellénius ML; Troutt JS; Konrad RJ; Öhrvik J; Hamsten A; de Faire U
    Circulation; 2016 Mar; 133(13):1230-9. PubMed ID: 26896437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of low levels of vascular endothelial growth factor after myocardial infarction on 6-month clinical outcome. Results from the Nagoya Acute Myocardial Infarction Study.
    Matsudaira K; Maeda K; Okumura N; Yoshikawa D; Morita Y; Mitsuhashi H; Ishii H; Kondo T; Murohara T;
    Circ J; 2012; 76(6):1509-16. PubMed ID: 22452999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study.
    Chen R; Zhao H; Zhou J; Wang Y; Li J; Zhao X; Li N; Liu C; Zhou P; Chen Y; Song L; Yan H
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.